5. Bibliografía

-Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013; 133:377-85.

-Ferrándiz C, Carrascosa JM, Toro M. Prevalence of psoriasis in Spain in the age of biologics. Actas Dermosifiliogr. 2014; 105:504-9.

-Fernández-Armenteros JM, Gómez-Arbonés X, Buti-Solé M, Betriu-Bars A, Sanmartin-Novell V, Ortega-Bravo M, Martínez-Alonso M, Casanova-Seuma JM. Epidemiology of Psoriasis. A Population-Based Study. Actas Dermosifiliogr. 2019; 110:385-392.

-Boehncke WH. Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Front Immunol. 2018; 9:579.

–Fernández-Armenteros JM, Gómez-Arbonés X, Buti-Soler M, Betriu-Bars A, Sanmartin-Novell V, Ortega-Bravo M, Martínez-Alonso M, Garí E, Portero-Otín M, Santamaria-Babi L, Casanova-Seuma JM. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study. J Eur Acad Dermatol Venereol. 2019; 33:128-135.

-Lomholt G. Psoriasis on the Faroe Islands; a preliminary report. Acta Derm Venereol. 1954; 34:92.

-Farber EM, Nall ML, Watson W. Natural History of Psoriasis in 61 Twin Pairs. JAMA Dermatology 1974; 109:207–211.

-Trembath RC, Clough RL, Rosbotham JL, Jones AB, Camp RD, Frodsham A, Browne J, Barber R, Terwilliger J, Lathrop GM, Barker JN. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997; 6:813–820.

-Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018; 178:854-862.

-Mellett M, Meier B, Mohanan D, Schairer R, Cheng P, Satoh TK, Kiefer B, Ospelt C, Nobbe S, Thome M, Contassot E, French LE. CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23/IL-17-Mediated Psoriasiform Skin Inflammation In Vivo. J Invest Dermatol. 2018; 138:2010-2023.

-de Cid R, Riveira-Munoz E, Zeeuwen PL, Robarge J, Liao W, Dannhauser EN, Giardina E, Stuart PE, Nair R, Helms C, Escaramís G, Ballana E, Martín-Ezquerra G, den Heijer M, Kamsteeg M, Joosten I, Eichler EE, Lázaro C, Pujol RM, Armengol L, Abecasis G, Elder JT, Novelli G, Armour JA, Kwok PY, Bowcock A, Schalkwijk J, Estivill X. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 2009; 41:211–215.

-Strange A, Capon F, Spencer CC, Knight J, Weale ME, Allen MH, Barton A, Band G, Bellenguez C, Bergboer JG, Blackwell JM, Bramon E, Bumpstead SJ, Casas JP, Cork MJ, Corvin A, Deloukas P, Dilthey A, Duncanson A, Edkins S, Estivill X, Fitzgerald O, Freeman C, Giardina E, Gray E, Hofer A, Hüffmeier U, Hunt SE, Irvine AD, Jankowski J, Kirby B, Langford C, Lascorz J, Leman J, Leslie S, Mallbris L, Markus HS, Mathew CG, McLean WH, McManus R, Mössner R, Moutsianas L, Naluai AT, Nestle FO, Novelli G, Onoufriadis A, Palmer CN, Perricone C, Pirinen M, Plomin R, Potter SC, Pujol RM, Rautanen A, Riveira-Munoz E, Ryan AW, Salmhofer W, Samuelsson L, Sawcer SJ, Schalkwijk J, Smith CH, Ståhle M, Su Z, Tazi-Ahnini R, Traupe H, Viswanathan AC, Warren RB, Weger W, Wolk K, Wood N, Worthington J, Young HS, Zeeuwen PL, Hayday A, Burden AD, Griffiths CE, Kere J, Reis A, McVean G, Evans DM, Brown MA, Barker JN, Peltonen L, Donnelly P, Trembath RC. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010; 42:985–99.

-Dand N, Mahil SK, Capon F, Smith CH, Simpson MA, Barker JN. Psoriasis and Genetics. Acta Derm Venereol. 2020; 100:adv00030. doi: 10.2340/00015555-3384.

-Sieminska I, Pieniawska M, Grzywa TM. The immunology of psoriasis-current concepts in pathogenesis. Clin Rev Allergy Immunol. 2024;66(2):164-191.

-Morizane S, Gallo RL. Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol. 2012; 39:225–30.

-Rauschenberger T, Schmitt V, Azeem M, Klein-Hessling S, Murti K, Grän F, Goebeler M, Kerstan A, Klein M, Bopp T, Serfling E, Muhammad K. T cells control chemokine secretion by keratinocytes. Front Immunol. 2019; 10:1917.

-Shao S, Fang H, Dang E, Xue K, Zhang J, Li B, Qiao H, Cao T, Zhuang Y, Shen S, Zhang T, Qiao P, Li C, Gudjonsson JE, Wang G. Neutrophil Extracellular Traps Promote Inflammatory Responses in Psoriasis via Activating Epidermal TLR4/IL-36R Crosstalk. Front Immunol. 2019; 10:746.

–Ariza ME, Williams MV, Wong HK. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application. Clin Immunol. 2013; 146:131–9.

-Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018; 55:379-390.

–Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009; 160:319–24.

–Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009; 361:888–98.

-Beringer A, Noack M, Miossec P. Il-17 in chronic inflammation: from discovery to targeting. Trends Mol Med. 2016; 22:230–41.

-Lorthois I, Asselineau D, Seyler N, Pouliot R. Contribution of in vivo and organotypic 3d models to understanding the role of macrophages and neutrophils in the pathogenesis of psoriasis. Mediators Inflamm. 2017; 2017:7215072.

–Desplat-Jégo S, Burkly L, Putterman C. Targeting TNF and its family members in autoimmune/inflammatory disease. Mediators Inflamm. 2014; 2014:628748.

-Ebbo M, Crinier A, Vély F, Vivier E. Innate lymphoid cells: major players in inflammatory diseases. Nat Rev Immunol. 2017; 17:665–78.

–Rebora A. Cyclosporine A in psoriasis. Clin Dermatol. 1991; 9:515–22.

–Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014; 14:585–600.

–Hugh JM, Weinberg JM. Update on the pathophysiology of psoriasis. Cutis. 2018; 102 5S:6–12.

-Polese B, Zhang H, Thurairajah B, King IL. Innate Lymphocytes in Psoriasis. Front Immunol. 2020; 11:242.

-Khalil S, Bardawil T, Kurban M, Abbas O. Tissue-resident memory T cells in the skin. Inflamm Res. 2020; 69:245-254.

-Canal-García E, Bosch-Amate X, Belinchón I, Puig L. Nail psoriasis. Actas Dermo-Sifiliográficas. 2022; 113(5):T481-T490.

–Fernández-Armenteros JM, Molinero I, Castan E, Casanova JM. Perfiles psicológicos de los pacientes con psicodermatosis. Piel 2015; doi:10.1016.

-Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-7.

-Casanova JM, Ribera M. Actualización en el tratamiento de la psoriasis. FMC. Formación Médica Continuada en Atención Primaria 1998; 5:555-624.

-Casanova JM, Sanmartín V, Soria X, Ferran M, Pujol RM, Ribera M. Tratamiento tópico de la psoriasis. Piel 2009; 24:557-68.

-Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63:278-285.

-Yanovsky RL, Huang KP, Buzney EA. Optimizing Narrowband UVB Phototherapy Regimens for Psoriasis. Dermatol Clin. 2020; 38:1-10.

-Esmat S, Hegazy RA, Shalaby S, Hu SC, Lan CE. Phototherapy and Combination Therapies for Vitiligo. Dermatol Clin. 2017; 35:171-192.

-Ortiz-Salvador JM, Pérez-Ferriols A. Phototherapy in Atopic Dermatitis. Adv Exp Med Biol. 2017; 996:279-286.

-Legat FJ. The Antipruritic Effect of Phototherapy. Front Med (Lausanne). 2018; 5:333.

-Yu Z, Wolf P. How It Works: The Immunology Underlying Phototherapy. Dermatol Clin. 2020; 38:37-53.

-Raone B, Patrizi A, Gurioli C, Gazzola A, Ravaioli GM. Cutaneous carcinogenic risk evaluation in 375 patients treated with narrowband-UVB phototherapy: A 15-year experience from our Institute. Photodermatol Photoimmunol Photomed. 2018; 34:302-306.

-Karaosmanoglu N, Ozdemir Cetinkaya P, Kutlu O, Karaaslan E, Imren IG, Kiratli Nalbant E, Eksioglu M. A cross-sectional analysis of skin cancer risk in patients receiving narrow-band ultraviolet B phototherapy: an evaluation of 100 patients. Arch Dermatol Res. 2020; 312:249-253.

-Jacob J, Pona A, Cline A, Feldman S. Home UV Phototherapy. Dermatol Clin. 2020; 38:109-126.

-Richard EG. The Science and (Lost) Art of Psoralen Plus UVA Phototherapy. Dermatol Clin. 2020; 38:11-23.

-Kolios AG, Yawalkar N, Anliker M, Boehncke WH, Borradori L, Conrad C, Gilliet M, Häusermann P, Itin P, Laffitte E, Mainetti C, French LE, Navarini AA. Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. Dermatology. 2016; 232:385-406.

-Menting SP, Dekker PM, Limpens J, Hooft L, Spuls PI. Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation. Acta Derm Venereol. 2016; 96:23-8.

-Holliday AC, Moody MN, Berlingeri-Ramos A. Methotrexate: role of treatment in skin disease. Skin Therapy Lett. 2013; 18:4-9.

-Doutre MS. Ciclosporine. Ann Dermatol Venereol. 2002; 129(4 Pt 1):392-404.

-Casanova JM, Pujol R, Ribera M. Tratamiento de la psoriasis en placas moderada y grave con fármacos biológicos. Piel 2008; 23:475-7.

-Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019; 80:27-40.

-van Lümig PP, Driessen RJ, Roelofs-Thijssen MA, Boezeman JB, van de Kerkhof PC, de Jong EM. Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab. Br J Dermatol. 2011; 165:375-82.

-Boehncke WH, Brasie RA, Barker J, Chimenti S, Daudén E, de Rie M, Dubertret L, Giannetti A, Katsambas A, Kragballe K, Naeyaert JM, Ortonne JP, Peyrí J, Prinz JC, Saurat JH, Strohal R, van de Kerkhof P, Sterry W; European Dermatology Expert Group. Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. J Eur Acad Dermatol Venereol. 2006; 20:988-98.

-Bedini C, Nasorri F, Girolomoni G, Pita OD, Cavani A. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br J Dermatol 2007; 157:249–58.

-Casanova JM, Sanmartin V, Baradad M, Ferran M, Pujol RM, Ribera M. Tratamiento de la psoriasis en placas moderada y grave con infliximab. Piel: formación continuada en dermatologia. 2008; 23:523-528.

-Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152:1304-12.

-Gordon KB, Gottlieb AB, Leonardi CL, Elewski BE, Wang A, Jahreis A, Zitnik R. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat 2006; 17:9-17.

–Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A; Etanercept Pediatric Psoriasis Study Group. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358:241-51.

-Dapavo P, Vujic I, Fierro MT, Quaglino P, Sanlorenzo M. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016; 75:736-9.

-Griffiths CE, Thaçi D, Gerdes S, Arenberger P, Pulka G, Kingo K, Weglowska J; EGALITY study group, Hattebuhr N, Poetzl J, Woehling H, Wuerth G, Afonso M. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2016 Oct 27. doi: 10.1111/bjd.15152.

-Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Narbutt J, Philipp S, Spelman L, Weglowska J, Zhang N, Strober B. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017. pii: S0190-9622(16)31238-5.

-Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, Peterson L, Arendt C, Burge D, Reich K. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018; 79:302-314.

-Lebwohl M, Blauvelt A, Paul C, Sofen H, Węgłowska J, Piguet V, Burge D, Rolleri R, Drew J, Peterson L, Augustin M. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018; 79:266-276.

-Clowse ME, Wolf DC, Förger F, Cush JJ, Golembesky A, Shaughnessy L, De Cuyper D, Mahadevan U. Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol. J Rheumatol. 2015; 42:2270-8.

-van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsanos K, Kolacek S, Juillerat P, Mulders AG, Pedersen N, Selinger C, Sebastian S, Sturm A, Zelinkova Z, Magro F; European Crohn’s and Colitis Organization. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015; 9:107-24.

-Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011; 164:1091-6.

-Lynde CW, Gupta AK, Guenther L, Poulin Y, Levesque A, Bissonnette R. A randomized study comparing the combination of nbUVB and etanercept to etanercept  monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. J Dermatolog Treat. 2012; 23:261-7.

-Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, Menter A, Philipp S, Sofen H, Tyring S, Berner BR, Visvanathan S, Pamulapati C, Bennett N, Flack M, Scholl P, Padula SJ. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2017; 376:1551-1560.

-Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019; 394(10198):576-586.

-Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665-74.

-Garcia-Valladares I, Cuchacovich R, Espinoza LR. Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. Drug Des Devel Ther. 2011; 5:41-9

-Krulig E, Gordon KB. Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid. 2010; 5:11-22.

-Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong  AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019; 80:1029-1072.

-Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomized controlled trial. Lancet. 2019; 394(10201):831-839.

-Puig L. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. Expert Rev Clin Immunol. 2019; 15:589-597.

-Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, van der Heijde D, McInnes IB; DISCOVER-2 Study Group. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020; 395(10230):1126-1136.

-Frampton JE. Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis. Am J Clin Dermatol. 2019;20(2):295-306.

-Gu C, Yang J. Risankizumab for the treatment of psoriasis. Expert Rev Clin Pharmacol. 2019;12(9):851-857.

-Ouellette AJ. Paneth cells and innate mucosal immunity. Curr Opin Gastroenterol. 2010;26:547-553.

-Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow CK, Barmettler B, Nelson J, Bina H, Huang L, Wroblewski VJ, Kikly K. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016; 9:39-50.

-Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, Purdy D, Fitch E, Iordanov M, Blauvelt A. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol. 2009; 129:2175-2183.

-Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013; 168:402-411.

-Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014; 371:326-338.

-Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, Shima T, Papavassilis C, Nakagawa H; ERASURE Study Japanese subgroup. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol. 2014; 41:1039-1046.

-Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015; 386(9993):541-51.

-Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016; 375:345-56.

-Blauvelt A. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis. Expert Opin Biol Ther. 2016; 16:255-63.

-Blauvelt A, Papp KA, Griffiths CE, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). Am J Clin Dermatol. 2017. doi: 10.1007/s40257-016-0246-9.

-Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, Shrom D, Amato D, Okubo Y, Reich K. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate to severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, -2, and -3). J Eur Acad Dermatol Venereol. 2017. doi: 10.1111/jdv.14237.

-Reich K, Leonardi C, Lebwohl M, Kerdel F, Okubo Y, Romiti R, Goldblum O, Dennehy EB, Kerr L, Sofen H. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2016; 13:1-6.

-Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, Cameron GS, Osuntokun OO; Japanese Ixekizumab Study Group. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized postular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2016. doi: 10.1111/1346-8138.13622.

-Leonardi CL, Blauvelt A, Sofen HL, Gooderham M, Augustin M, Burge R, Zhu B, Reich K. Rapid Improvements in Health-related Quality of Life and Itch with Ixekizumab Treatment in Randomized Phase 3 Trials: Results from UNCOVER-2 and UNCOVER-3. J Eur Acad Dermatol Venereol. 2017. doi: 10.1111/jdv.14211.

-Armstrong AW, Lynde CW, McBride SR, Ståhle M, Edson-Heredia E, Zhu B, Amato D, Nikaï E, Yang FE, Gordon KB. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. JAMA Dermatol. 2016; 152:661-9.

-Gottlieb AB, Saure D, Wilhelm S, Dossenbach M, Schuster C, Smith SD, Ramot Y, Thaçi D. Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis – efficacy findings up to week 12. J Dermatolog Treat. 2020 Apr 17:1-8.

-Facheris P, Valenti M, Pavia G, Guanziroli E, Narcisi A, Borroni RG, Costanzo A. Brodalumab: a new way to inhibit IL-17 in psoriasis. Dermatol Ther. 2020:e13403.

-Puig L. Brodalumab: the first anti-IL-17 receptor agent for psoriasis. Drugs Today (Barc). 2017; 53:283-297.

-Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB), Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016; 175:273-86.

-Papp K, Menter A, Leonardi C, Soung J, Weiss S, Pillai R, Jacobson A. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomised phase 3 trial (AMAGINE-1). Br J Dermatol. 2020. doi: 10.1111/bjd.19132.

-Sawyer L, Fotheringham I, Wright E, Yasmeen N, Gibbons C, Holmen Møller A. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. J Dermatolog Treat. 2018; 29:557-568.

-Elewski B, Rich P, Lain E, Soung J, Lewitt GM, Jacobson A. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatolog Treat. 2020, 21:1-5.

-Gordon KB, Langley RG, Warren RB, et al. Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials. JAMA Dermatol. 2022; 158(7):735.

–Gottlieb AB, Leonardi CL, Goffe BS, Ortonne JP, van der Kerkhof PC, Zitnik R, Nakanishi A, Jahreis A. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006; 54(Suppl):S92-100.

-Dávila-Seijo P, Dauden E, Descalzo MA, Carretero G, Carrascosa JM, Vanaclocha F, Gómez-García FJ, De la Cueva-Dobao P, Herrera-Ceballos E, Belinchón I, López-Estebaranz JL, Alsina M, Sánchez-Carazo JL, Ferrán M, Torrado R, Ferrandiz C, Rivera R, Llamas M, Jiménez-Puya R, García-Doval I. BIOBADADERM Study Group. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. J Invest Dermatol. 2017; 137:313-321.

-Yamaguchi Y, Takatsu N, Ootaki K, Nakagawa H. Long-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study. J Dermatol. 2020. doi: 10.1111/1346-8138.15343.

-Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-5.

-Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 2005; 4:637-41.

-Ahmad K, Rogers S. Two years of experience with etanercept in recalcitrant psoriasis. Br J Dermatol 2007; 156:1010-4.

-Fabroni C, Gori A, Prignano F, Lotti T. A severe complication of anti-TNF alfa treatment. G Ital Dermatol Venereol 2010; 145:775-7.

-Chang MB, Sri JC, Driscoll M, Gaspari AA. Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers. J Drugs Dermatol. 2011; 10:914-6.

-Tektonidou MG, Skopouli FN. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?. Clin Rheumatol 2007; 27:541-2

-Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-104.

-Lim WS, Powell RJ, Johnston ID. Tuberculosis and treatment with infliximab. N Engl J Med 2002; 346:623-6.

-Kasiraman V, Atwan AA, Durojaiye OC, Kalavala M, Piguet V Risk of tuberculosis with the use of anti-TNF medications in psoriasis: incidence, screening and management.Dermatol Online J. 2014; pii: 13030/qt8s09h73j.

-Theis VS, Rhodes JM. Review article: minimising Tuberculosis during anti-TNF-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27:19-30.

-Armstrong AW, Aldredge L, Yamauchi PS. Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners. J Cutan Med Surg. 2016; 20:196-206.

-Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 2011; 50:1700-11.

-Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008; 67:710-2.

-Mestre M, Bourrel R, Paul C, Montastruc JL, Sommet A. Infectious risk of biological drugs vs. traditional systemic treatments in moderate-to-severe psoriasis: a cohort analysis in the French insurance database. Fundam Clin Pharmacol. 2018; 32:436-449.

-Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011; 306:864-71.

-Kerdel FA, Valeron-Almazán P, Vitiello M, Abuchar A. Exacerbation and change of psoriasis morphology in a patient treated with ustekinumab. J Cutan Med Surg. 2011; 15:183-4.

-Balda A, Wani I, Roohi TF, Suman, Krishna KL, Mehdi S, Nadiga AP, Makkapati M, Baig MAI. Psoriasis and skin cancer – Is there a link? Int Immunopharmacol. 2023; 121:110464.

-Crowley JJ, Warren RB, Cather JC. Safety of selective IL23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019; 33:1676-84.

-Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V,Pathan R, Papavassilis C, Cooper S; FEATURE Study Group. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015; 172:484-493.

-Ley K, Smith E, Stark MA. IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol Res. 2006; 34:229–242.

-McInnes IB, Sieper J, Braun J, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014; 73:349-356.

-Reich K, Leonardi C, Langley RG, Warren RB, Bachelez H, Romiti R, Ohtsuki M, Xu W, Acharya N, Solotkin K, Colombel JF, Hardin DS. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017; 76:441-448.

-Rungapiromnan W, Yiu ZZ, Warren RB, Griffiths CE, Ashcroft DM. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2016. doi: 10.1111/bjd.14964.

-Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, Ferris LK, Paul C, Lebwohl M, Braun DK, Mallbris L, Wilhelm S, Xu W, Ljungberg A, Acharya N, Reich K. Short and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol. 2016. pii: S0190-9622(16)30868-4.

-Beck KM, Koo J. Brodalumab for the treatment of plaque psoriasis: up-to-date. Expert Opin Biol Ther. 2019; 19:287-292.

-Cai Q, Teeple A, Wu B, Muser E. Prevalence and economic burden of comorbid anxiety and depression among patients with moderate-to-severe psoriasis. J Med Econ. 2019; 22:1290-7.

-Carretero G, Ferrandiz C, Dauden E, Vanaclocha Sebastián F, Gómez-García FJ, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina-Gibert M, López-Estebaranz JL, Ferrán M, Torrado R, Carrascosa JM, Carazo C, Rivera R, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. J Eur Acad Dermatol Venereol. 2015; 29:156-63.

-Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020; 1:CD011535.

-James J, Otto T, Gao J, Porter ML. Oral psoriasis therapies. Dermatologic Clinics. 2024; 42(3):357-363.

-Barrea L, Balato N, Di Somma C, Macchia PE, Napolitano M, Savanelli MC, Esposito K, Colao A, Savastano S. Nutrition and psoriasis: is there any association between the severity of the disease and adherence to the Mediterranean diet? J Transl Med. 2015; 13:18.

-Phan C, Touvier M, Kesse-Guyot E, Adjibade M, Hercberg S, Wolkenstein P, Chosidow O, Ezzedine K, Sbidian E. Association Between Mediterranean Anti-inflammatory Dietary Profile and Severity of Psoriasis: Results From the NutriNet-Santé Cohort. JAMA Dermatol. 2018; 154:1017-1024.

-Molina-Leyva A, Cuenca-Barrales C, Vega-Castillo JJ, Ruiz-Carrascosa JC, Ruiz-Villaverde R. Adherence to Mediterranean diet in Spanish patients with psoriasis: Cardiovascular benefits? Dermatol Ther. 2019; 32:e12810.

-Ruiz-Romeu E, Ferran M, de Jesús-Gil C, García P, Sagristà M, Casanova JM, Fernández JM, Chiriac A, Hóllo P, Celada A, Pujol RM, Santamaria-Babí LF. Microbe-Dependent Induction of IL-9 by CLA(+) T Cells in Psoriasis and Relationship with IL-17A. J Invest Dermatol. 2018; 138:580-587.

-Garritsen FM, Kraag DE, de Graaf M. Guttate psoriasis triggered by perianal streptococcal infection. Clin Exp Dermatol. 2017; 42:536-538

-Pfingstler LF, Maroon M, Mowad C. Guttate psoriasis outcomes. Cutis. 2016; 97:140-4.

-Wu W, Debbaneh M, Moslehi H, Koo J, Liao W. Tonsillectomy as a treatment for psoriasis: a review. J Dermatolog Treat. 2014; 25:482-6.

-Owen CM, Chalmers R, O’Sullivan T, Griffiths CE. WITHDRAWN: Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database Syst Rev. 2019; 3:CD001976.

-Maruani A, Samimi M, Stembridge N, Abdel Hay R, Tavernier E, Hughes C, Le Cleach L. Non-antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis. Cochrane Database Syst Rev. 2019; 4:CD011541.

-Chalmers R, O’Sullivan T, Owen CM, Griffiths CE. WITHDRAWN: Interventions for guttate psoriasis. Cochrane Database Syst Rev. 2019; 4:CD001213.

-Zhang P, Chen HX, Xing JJ, Jin Z, Hu F, Li TL, Zhou XY. Clinical analysis of 84 cases of erythrodermic psoriasis and 121 cases of other types of erythroderma from 2010-2015. J Huazhong Univ Sci Technolog Med Sci. 2017; 37:563-567.

-Egeberg A, Thyssen JP, Gislason GH, Skov L. Prognosis after Hospitalization for Erythroderma. Acta Derm Venereol. 2016; 96:959-962.

-Heinrich M. Cook E, Roach J, Juarez RM, Payne D, Atkins R, Stetson C. Erythrodermic psoriasis secondary to systemic corticosteroids. Proc (Bayl Univ Med Cent). 2019; 33:113-114.

-Rendo M, Boster J, Dalton SR, Yun H. An Uncommon Presentation of Erythrodermic Psoriasis in a Patient Without a History of Psoriasis. Cureus. 2019; 11:e5099. doi: 10.7759/cureus.5099.

-Yamasaki K, Nakagawa H, Kubo Y, Ootaki K; Japanese Brodalumab Study Group. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017; 176:741-751.

-Megna M, Gallo L, Balato N, Balato A. A case of erythrodermic psoriasis successfully treated with ixekizumab. Dermatol Ther. 2019; 32:e12825. doi: 10.1111/dth.12825.

-Pizzatti L, Mugheddu C, Sanna S, Atzori L, Rongioletti F. Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab. Dermatol Ther. 2020:e13348. doi: 10.1111/dth.13348.

-Cuellar-Barboza A, Ocampo-Candiani J, Herz-Ruelas ME. A Practical Approach to the Diagnosis and Treatment of Adult Erythroderma. Actas Dermosifiliogr. 2018; 109:777-790.

-Pathak GN, Wang E, Dhillon J, Parikh PN, Esseghir R, Rao BK, Feldman SR. Spesolimab: a review of the first il-36 blocker approved for generalized pustular psoriasis. Ann Pharmacother. Ann Pharmacother. 2025; 59(2):174-183.

-Westphal DC, Schettini AP, Souza PP, Castiel J, Chirano CA, Santos M. Generalized pustular psoriasis induced by systemic steroid dose reduction. An Bras Dermatol. 2016; 91:664-666.

-Weisenseel P, Wilsmann-Theis D, Kahl C, Reich K, Mössner R. Pustulöse Psoriasis. Hautarzt. 2016; 67:445-53.

-Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, Köks S, Kingo K, Smith C, Barker JN; ERASPEN Network European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017; 31:1792-1799.

-Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments. Am J Clin Dermatol. 2020. doi: 10.1007/s40257-020-00503-5.

–Engin B, Aşkın Ö, Tüzün Y. Palmoplantar psoriasis. Clin Dermatol. 2017; 35:19-27.

-Cornelius V, Wilson R, Cro S, Barker J, Burden D, Griffiths CEM, Lachmann H, McAteer H, Reynolds N, Pink A, Warren RB, Capon F, Smith C. A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. Trials. 2018; 19:465)

-Bachelez H. Pustular psoriasis and related pustular skin diseases. Br J Dermatol. 2018; 178:614-618.

-Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018; 32:1645-1651.

-Robinson A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF Jr, Kalb RE. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012; 67:279-88.

-Sheu JS, Divito SJ, Enamandram M, Merola JF. Dapsone Therapy for Pustular Psoriasis: Case Series and Review of the Literature. Dermatology. 2016; 232:97-101.

-Levin EC, Debbaneh M, Koo J, Liao W. Biologic therapy in erythrodermic and pustular psoriasis. J Drugs Dermatol. 2014; 13:342-54.

-Okubo Y, Mabuchi T, Iwatsuki K, Elmaraghy H, Torisu-Itakura H, Morisaki Y, Nakajo K. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J). J Eur Acad Dermatol Venereol. 2019; 33:325-332.

-Ho PH, Tsai TF. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work. J Dermatol. 2018; 45:1353-1356.

-Borda LJ, Wikramanayake TC. Seborrheic Dermatitis and Dandruff: A Comprehensive Review. J Clin Investig Dermatol. 2015; 3. doi: 10.13188/2373-1044.1000019.

-Tucker D, Masood S. Seborrheic dermatitis. In: StatPearls. StatPearls Publishing; 2024.

-Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015; 91:185-90.

-Mehta AB, Nadkarni NJ, Patil SP, Godse KV, Gautam M, Agarwal S. Topical corticosteroids in dermatology. Indian J Dermatol Venereol Leprol. 2016; 82:371-8.

-Borda LJ, Perper M, Keri JE. Treatment of seborrheic dermatitis: a comprehensive review. J Dermatolog Treat. J Dermatolog Treat. 2019; 30:158-169.

–Leung AKC, Lam JM, Leong KF, Hon KL. Pityriasis rosea: an updated review. Curr Pediatr Rev. 2021; 17(3):201-211.

-Mahajan K, Relhan V, Relhan AK, Garg VK. Pityriasis Rosea: An Update on Etiopathogenesis and Management of Difficult Aspects. Indian J Dermatol. 2016; 61:375-84.

-Villalon-Gomez JM. Pityriasis Rosea: Diagnosis and Treatment. Am Fam Physician. 2018; 97:38-44.

-Gimenez-García R, Pérez-Castrillón JL. Liquen plano y enfermedades asociadas: estudio clinicoepidemiológico. Actas Dermosifiliogr 2004; 95:154-60.

-Gorouhi F, Davari P, Fazel N. Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. ScientificWorldJournal. 2014; 2014:742826.

-Abal L, Soria X, Casanova JM. Alopecias cicatriciales. Actas Dermosif 2012; 103:345-452.

-Solimani F, Forchhammer S, Schloegl A, Ghoreschi K, Meier K. Lichen planus – a clinical guide. J Deutsche Derma Gesell. 2021; 19(6):864-882.

-Usatine RP, Tinitigan M. Diagnosis and treatment of lichen planus. Am Fam Physician. 2011; 84:53-60.

-Sun SL, Liu JJ, Zhong B, Wang JK, Jin X, Xu H, Yin FY, Liu TN, Chen QM, Zeng X. Topical calcineurin inhibitors in the treatment of oral lichen planus: a systematic review and meta-analysis. Br J Dermatol. 2019. doi: 10.1111/bjd.17898.

-Thongprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. Cochrane Database Syst Rev. 2011; (7):CD001168.